Cargando...
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Fabry disease (FD) is a progressive multisystemic disorder, treatable with recombinant enzyme replacement therapy (agalsidase). However, recent studies suggest an endogenous inhibition of agalsidase in patients with FD, as reported for other lysosomal storage diseases. To assess the clinical consequ...
Guardado en:
| Publicado en: | J Am Soc Nephrol |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society of Nephrology
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4696578/ https://ncbi.nlm.nih.gov/pubmed/25933799 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2014121226 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|